-
公开(公告)号：US20100055049A1
公开(公告)日：2010-03-04
申请号：US12374891
申请日：2007-07-27
申请人： Mei-Chang Kuo , Michael A. Eldon , YiQiong Yuan
发明人： Mei-Chang Kuo , Michael A. Eldon , YiQiong Yuan
CPC分类号： A61K9/0073 , A61K38/28
摘要： Aerosolizable formulations comprising: an insulin derivative having an isoelectric point (pI) ranging from about 6 to about 8; and a pharmaceutically acceptable excipient including a precipitating agent.
摘要翻译： 可气雾化的制剂，其包含：具有约6至约8的等电点（pI）的胰岛素衍生物; 和药学上可接受的赋形剂，包括沉淀剂。
-
2.发明申请Compositions and Methods for Achieving Sustained Therapeutic Drug Concentrations in a Subject 有权在主题中实现持续治疗药物浓度的组合物和方法公开(公告)号：US20110269789A1
公开(公告)日：2011-11-03
申请号：US13120551
申请日：2009-09-23
IPC分类号： A61K31/437 , A61P35/00 , C07D491/22 , A61K47/48 , C07C43/11
CPC分类号： A61K31/4745 , A61K47/60
摘要： Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo.
摘要翻译： 本文提供了当在体内施用时获得小分子抗癌剂的持续治疗作用的化合物和方法。
-
3.发明授权Compositions and methods for achieving sustained therapeutic drug concentrations in a subject 有权用于在受试者中实现持续治疗药物浓度的组合物和方法公开(公告)号：US08906353B2
公开(公告)日：2014-12-09
申请号：US13120551
申请日：2009-09-23
CPC分类号： A61K31/4745 , A61K47/60
摘要： Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo.
摘要翻译： 本文提供了当在体内施用时获得小分子抗癌剂的持续治疗作用的化合物和方法。
-
公开(公告)号：US20110160186A1
公开(公告)日：2011-06-30
申请号：US12993807
申请日：2009-06-09
IPC分类号： A61K31/55 , A61K31/135 , A61K31/495 , C12Q1/26 , A61K31/472 , A61K31/138 , A61K31/5377 , C07D217/04 , C07C215/28 , C07D417/04 , C07D295/088 , C07D223/28 , A61P3/00
CPC分类号： A61K47/60
摘要： The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene.
摘要翻译： 本发明提供包括施用与水溶性低聚物共价结合的CYP2D6生物活性药物的各种方法。 CYP2D6生物活性药物偶联物的代谢从CYP2D6转向替代途径，因此可以利用缀合物来减轻CYP2D6基因遗传多态性引起的人口间变异相关的问题。
-
公开(公告)号：US07326691B2
公开(公告)日：2008-02-05
申请号：US11158332
申请日：2005-06-21
申请人： Sarma Duddu , Srinivas Palakodaty , David Lechuga-Ballesteros , Danforth Miller , Alan R. Kugler , Christopher Frantz , Trixie Tan , Richard Malcolmson , Keith Washco , Theresa Sweeney , Thomas E. Tarara , Sarvajna Dwivedi , Michael A. Eldon
发明人： Sarma Duddu , Srinivas Palakodaty , David Lechuga-Ballesteros , Danforth Miller , Alan R. Kugler , Christopher Frantz , Trixie Tan , Richard Malcolmson , Keith Washco , Theresa Sweeney , Thomas E. Tarara , Sarvajna Dwivedi , Michael A. Eldon
CPC分类号： A61K9/0075 , A61K9/1611 , A61K9/1617 , A61K9/1694 , A61K31/7048 , A61M15/0028 , A61M15/0041 , A61M2202/064
摘要： A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 μm to about 1.9 μm. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about 80 wt % of the particles have a geometric diameter ranging from about 1.1 μm to about 1.9 μm. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 μm, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.
摘要翻译： 组合物包括包含至少约95重量％的两性霉素B的颗粒，其中所述颗粒的质量中值直径范围为约1.1μm至约1.9μm。 另一种组合物还包括包含至少约95wt％的两性霉素B的颗粒，其中至少约80wt％的颗粒具有约1.1μm至约1.9μm的几何直径。 另一种组合物包括包括两性霉素B的颗粒，其中颗粒的质量中值直径小于约1.9μm，并且其中两性霉素B的结晶度水平至少为约20％。 单位剂量形式，递送系统和方法可以涉及类似的组合物。
-
公开(公告)号：US11033631B2
公开(公告)日：2021-06-15
申请号：US12993807
申请日：2009-06-09
IPC分类号： A61K31/155 , A61K31/145 , A61K8/43 , A61K47/60 , A61P9/12
摘要： The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene.
-
7.发明授权Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use 有权用于肺部给予抗真菌剂的制剂，以及相关的制造和使用方法公开(公告)号：US08404217B2
公开(公告)日：2013-03-26
申请号：US11187757
申请日：2005-07-22
IPC分类号： A61L9/04
CPC分类号： A61K31/7048 , A61K9/0075 , A61K9/1617
摘要： Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well.
摘要翻译： 提供了向患者肺部给予抗真菌剂的制剂。 还提供了使用制剂治疗抗真菌感染的方法，包括用两性霉素B的制剂治疗肺曲霉病。 还提供了制备制剂以达到最佳性能的方法。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.022 秒)
